LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Mersana Therapeutics Inc

Closed

SectorHealthcare

0.38 5.56

Overview

Share price change

24h

Current

Min

0.35

Max

0.39

Key metrics

By Trading Economics

Income

-10M

-24M

Sales

-14M

2.8M

EPS

-0.19

Profit margin

-875.926

Employees

102

EBITDA

-10M

-23M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+710.81% upside

Dividends

By Dow Jones

Next Earnings

12 Aug 2025

Market Stats

By TradingEconomics

Market Cap

1.7M

47M

Previous open

-5.18

Previous close

0.38

News Sentiment

By Acuity

25%

75%

56 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Mersana Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

10 Jan 2025, 12:00 UTC

Major Market Movers

Mersana Shares Rise on Advances With Breast-Cancer Treatment

Peer Comparison

Price change

Mersana Therapeutics Inc Forecast

Price Target

By TipRanks

710.81% upside

12 Months Forecast

Average 3 USD  710.81%

High 3 USD

Low 3 USD

Based on 5 Wall Street analysts offering 12 month price targets forMersana Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

0.311 / 0.355Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

56 / 380 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Mersana Therapeutics Inc

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.